Stereotactic radiosurgery for cerebral arteriovenous malformations: evaluation of long-term outcomes in a multicenter cohort

Robert M. Starke, MD, MSc,¹ Hideyuki Kano, MD,² Dale Ding, MD,¹ John Y. K. Lee, MD,³ David Mathieu, MD,⁴ Jamie Whitesell,³ John T. Pierce, MS,³ Paul P. Huang, MD,⁵ Douglas Kondziolka, MD,⁵ Chun-Po Yen, MD,¹ Caleb Feliciano, MD,⁶ Rafael Rodriguez-Mercado, MD,⁶ Luis Almodovar, MD,⁶ Daniel R. Pieper, MD,⁷ Inga S. Grills, MD,⁷ Danilo Silva, MD,⁸ Mahmoud Abbassy, MD,⁸ Symeon Missios, MD,⁸ Gene H. Barnett, MD,⁸ L. Dade Lunsford, MD,² and Jason P. Sheehan, MD, PhD¹

¹Department of Neurosurgery, University of Virginia, Charlottesville, Virginia; ²Department of Neurosurgery, University of Pittsburgh; ³Gamma Knife Center, University of Pennsylvania, Philadelphia, Pennsylvania; ⁴Department of Neurosurgery, University of Sherbrooke, Quebec, Canada; ⁵Gamma Knife Center, New York University, New York, New York; ⁶Department of Neurosurgery, University of Puerto Rico, San Juan, Puerto Rico; ⁷Gamma Knife Center, Beaumont Health System, Royal Oak, Michigan; and ⁸Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio

OBJECTIVE In this multicenter study, the authors reviewed the results following Gamma Knife radiosurgery (GKRS) of cerebral arteriovenous malformations (AVMs), determined predictors of outcome, and assessed predictive value of commonly used grading scales based upon this large cohort with long-term follow-up.

METHODS Data from a cohort of 2236 patients undergoing GKRS for cerebral AVMs were compiled from the International Gamma Knife Research Foundation. Favorable outcome was defined as AVM obliteration and no posttreatment hemorrhage or permanent symptomatic radiation-induced complications. Patient and AVM characteristics were assessed to determine predictors of outcome, and commonly used grading scales were assessed.

RESULTS The mean maximum AVM diameter was 2.3 cm, with a mean volume of 4.3 cm³. A mean margin dose of 20.5 Gy was delivered. Mean follow-up was 7 years (range 1–20 years). Overall obliteration was 64.7%. Post-GKRS hemorrhage occurred in 165 patients (annual risk 1.1%). Radiation-induced imaging changes occurred in 29.2%; 9.7% were symptomatic, and 2.7% had permanent deficits. Favorable outcome was achieved in 60.3% of patients. Patients with prior nidus embolization (OR 2.1, $p < 0.001$), prior AVM hemorrhage (OR 1.3, $p = 0.007$), eloquent location (OR 1.3, $p = 0.029$), higher volume (OR 1.01, $p < 0.001$), lower margin dose (OR 0.9, $p < 0.001$), and more isocenters (OR 1.1, $p = 0.011$) were more likely to have unfavorable outcomes in multivariate analysis. The Spetzler-Martin grade and radiosurgery-based AVM score predicted outcome, but the Virginia Radiosurgery AVM Scale provided the best assessment.

CONCLUSIONS GKRS for cerebral AVMs achieves obliteration and avoids permanent complications in the majority of patients. Patient, AVM, and treatment parameters can be used to predict long-term outcomes following radiosurgery.

<http://thejns.org/doi/abs/10.3171/2015.9.JNS151311>

KEY WORDS stereotactic radiosurgery; Gamma Knife; arteriovenous malformation; hemorrhage; embolization; surgery; radiation; grading; scale; complication; outcome; visual disorders

ALTHOUGH cerebral arteriovenous malformations (AVMs) are uncommon,^{1,36} they often present in young patients, leading to significant overall morbidity and even mortality.¹⁹ Despite the controversial benefit of intervention for unruptured AVMs, radiosurgery has

been used to achieve safe and complete obliteration of nidi that are often noted to entail high risks for hemorrhage and treatment with resection. The outcomes of AVM radiosurgery take several years to become apparent, and patients are at continued risk of hemorrhage prior to complete

ABBREVIATIONS ARUBA = A Randomized Trial of Unruptured Brain AVMs; AUC = area under the receiver operating characteristic curve; AVM = arteriovenous malformation; GKRS = Gamma Knife radiosurgery; mHR = hazard ratio in the presence of mortality risk; RBAS = radiosurgery-based AVM score (modified version); SAIVM = Scottish Audit of Intracranial Vascular Malformations; VRAS = Virginia Radiosurgery AVM Scale.

SUBMITTED June 6, 2015. **ACCEPTED** September 9, 2015.

INCLUDE WHEN CITING Published online March 4, 2016; DOI: 10.3171/2015.9.JNS151311.

obliteration. A number of patient and AVM characteristics have been suggested to predict outcome following radiosurgery, but studies are often limited due to small numbers of patients, single institution biases, and/or limited follow-up. In this multicenter study, we reviewed the results following Gamma Knife radiosurgery (GKRS) of cerebral AVMs treated across 2 decades, determined predictors of outcome, and assessed the predictive value of commonly used grading scales based upon this large cohort with long clinical follow-up.

Methods

Patient Population

Eight medical centers participating in the International Gamma Knife Research Foundation obtained individual institutional review board approvals to participate in this study. A total of 2236 patients were identified with cerebral AVMs treated with GKRS from 1988 to 2013. At each center, retrospective clinical outcome analysis of patients was performed. The following centers contributed data for this study: the University of Pittsburgh (758 patients), Cleveland Clinic (192 patients), New York University (103 patients), University of Sherbrooke (50 patients), University of Pennsylvania (33 patients), University of Puerto Rico (26 patients), Beaumont Health System (62 patients), and the University of Virginia (1012 patients).

The records of AVM patients who underwent Gamma Knife (Elekta AB) radiosurgery (GKRS) between 1988 and 2013 were evaluated by clinicians at each center for study inclusion. A database with selected variables was created and sent to all participating centers. Participating centers reviewed the medical records of their patients, entered the data in the spreadsheet, and removed all patient identifiers from the database. Pooled and de-identified data were screened for errors by an independent third party. Any uncertainties or ambiguities in the data were addressed by the contributing center. Afterward, data were transmitted to the first and senior authors who, along with their coauthors, developed this report.

Patients were included in the study if they had a cerebral AVM treated with GKRS. For inclusion, patients were required to have undergone a minimum of 12 months of neuroimaging and clinical follow-up after GKRS, but patients who suffered a complication within 12 months of treatment were also included. Patients with volume-staged radiosurgery were excluded.

Radiosurgical Technique

The Gamma Knife models U, B, C, 4C, or Perfexion were used, depending on the technology available at the time of GKRS for each participating center. The radiosurgery procedure began with the application of the Leksell model G stereotactic frame (Elekta AB), using local anesthetic supplemented by additional sedation as needed. After stereotactic frame placement, high-resolution, stereotactic MRI was performed. In cases for which MRI was not feasible or when MRI distortion was a concern, a stereotactic CT scan was obtained. Thin-slice axial and/or coronal plane images were obtained after intravenous contrast administration. Stereotactic cerebral angiography

was incorporated into treatment planning for nidus definition and dose planning. Radiosurgery dose planning was then performed by the neurosurgeon in conjunction with a radiation oncologist and medical physicist.

Clinical and Neuroimaging Follow-Up

Clinical and neuroimaging evaluations were generally performed at follow-up intervals of 6 months for the first 2 years after radiosurgery and then yearly afterward. When there was no nidus visible on MRI, the patient underwent angiography to confirm the obliteration of the nidus. All images were analyzed by both a neurosurgeon and a neuroradiologist. Patients were instructed to continue MRI follow-up every 1–5 years to monitor for long-term complications, even after their angiogram demonstrated complete AVM obliteration. For those patients for whom MRI was contraindicated (e.g., a cardiac pacemaker present), CT was performed instead. Whenever feasible, patients underwent follow-up neurological examination and neuroimaging at the respective treating center. However, because participating institutions represented tertiary referral centers, some patients underwent follow-up evaluations by their local physicians. For such patients, clinical notes and actual neuroimaging studies (i.e., not just the radiological reports) were received and reviewed by the treating clinicians who performed the GKRS procedure. The follow-up images were compared with the images obtained at the time of GKRS. AVM dimensions were assessed in the axial, sagittal, and coronal planes in relation to comparable measurements on the GKRS neuroimaging studies.

Statistical Analysis

Data are presented as median or mean and range for continuous variables, and as frequency and percentage for categorical variables. Calculations of normality were assessed graphically and statistically. Statistical analyses of categorical variables were carried out using chi-square and Fisher's exact test associations as appropriate. Statistics of means were carried out using the unpaired Student t-test, both with and without equal variance (Levene test) as necessary, and Wilcoxon rank-sum tests when variables were not normally distributed. Favorable outcome was defined as AVM obliteration and no posttreatment hemorrhage or permanent symptomatic complications following treatment. Patient, AVM, and treatment characteristics were assessed in univariate analysis to test covariates predictive of outcome. Clinically significant variables and interaction expansion covariates were both further assessed in multivariable analysis as deemed relevant. Factors predictive in univariate analysis ($p < 0.15$) were entered into multivariate logistic regression analysis models both with and without treatment characteristics.⁴ Eloquence was assessed according to the Spetzler-Martin grading scale, location was defined according to the updated²⁹ version of the modified radiosurgery-based AVM score (RBAS), and the Virginia Radiosurgery AVM Scale (VRAS) was defined as originally described (Table 1).³⁹ Additionally, competing risk survival analysis of AVM-free obliteration was calculated using the modified Kaplan-Meier method and Gray's method.¹⁷ After confirmation of the assump-

TABLE 1. Commonly used systems for grading AVMs

Grading System & Characteristic	Points Assigned	Coefficient
Spetzler-Martin grade		
Diameter (cm)		
Small (<3)	1	
Medium (3–6)	2	
Large (>6)	3	
Eloquence*		
No	0	
Yes	1	
Venous drainage		
Superficial only	0	
Deep	1	
RBAS score†		
Vol (cm ³)		0.1
Patient age (yrs)		0.02
Location‡		0.3
Hemispheric, corpus callosum, cerebellar = 0		
Basal ganglia, thalamus, brainstem = 1		
VRAS		
Vol (cm ³)		
1	0	
2–4	1	
>4	2	
History of hemorrhage		
No	0	
Yes	1	
Eloquence		
No	0	
Yes	1	

* Sensorimotor, language, or visual cortex; hypothalamus or thalamus; internal capsule; brainstem; cerebellar peduncles; or cerebellar nuclei.

† RBAS = (0.1)(volume) + (0.02)(patient age) + (0.3)(location).

‡ In the original RBAS, frontal and temporal location received 0 points; parietal, occipital, intraventricular, corpus callosum, and cerebellar received 1 point; and basal ganglia, thalamus, and brainstem received 2 points.

tion of proportional hazards, factors predictive of obliteration ($p < 0.15$) were entered into modified multivariate Cox regression analysis to assess hazard ratios in the presence of competing mortality risk (mHR).¹⁴ Multivariate regression models and commonly used grading scales were assessed using area under the receiver operating characteristic curve (AUC). Youden indices were calculated to determine cutoffs for the dichotomized continuous variable margin dose (Gy) that yielded the optimal discrimination of radiation-induced changes. A p value of less than or equal to 0.05 was considered statistically significant.

Results

Of the 2236 patients with cerebral AVMs, the mean age at the time of treatment was 36 years, and 49.6% were fe-

male (Table 2). The mean maximum AVM diameter was 2.3 cm, with a mean volume of 4.3 cm³. At the time of GKRS, the AVM volume was 0–2 cm³ in 35.3% of patients, 2–4 cm³ in 26.7%, and greater than 4 cm³ in 37.0%. Prior subtotal microsurgical resection was performed in 4.9% of patients, 1.1% had a history of CSF diversion, 8.5% had a history of radiotherapy, and 21.5% had a history of embolization.

The mean prescription dose delivered to the AVM margin was 20.5 Gy (median 20 Gy, range 5–36 Gy; Table 3). The mean prescription isodose line was 54.0% (median 50%, range 30%–100%). Most of the dose plans involved a multi-isocentric approach; a mean of 3.6 isocenters (median 3, range 1–43) were used.

Assessment of Obliteration

The mean follow-up after GKRS was 7 years (range 0.5–20 years). Overall, the rate of confirmation of MRI or angiographic obliteration was 64.7% at last follow-up. Complete angiographic obliteration was confirmed in 50.9% of cases, and MRI obliteration was present in another 13.8% of patients. The Kaplan-Meier actuarial rate of obliteration is demonstrated in Fig. 1. Patients with an AVM volume less than 4 cm³ and treated with more than 18 Gy were significantly more likely to have obliteration (77.3%) than those with an AVM greater than 4 cm³ and treated with less than 18 Gy (48.3%, $p < 0.001$). Independent predictors of overall obliteration in multivariate analysis were younger age (mHR 0.99, 95% CI 0.99–0.99, $p < 0.001$), lower nidus volume (mHR 0.96, 95% CI 0.94–0.98, $p < 0.001$), increasing year from when GKRS was performed (mHR 1.1, 95% CI 1.0–1.1, $p < 0.001$), and higher margin dose (mHR 1.1, 95% CI 1.0–1.1, $p < 0.001$).

Postradiosurgical Complications

Post-GRKS hemorrhage occurred in 165 patients in 15,362 years of follow-up, for an annual risk of 1.1% during the latency period. No hemorrhages were observed in patients with angiographic confirmation of obliteration. Patients with a history of hemorrhage were more likely to have post-GRKS hemorrhage (8.6%) than patients without a history of hemorrhage (6.3%, $p = 0.036$).

Radiation-induced imaging changes, consistent with transient or permanent increased perinidal T2-weighted changes on follow-up MRI, were radiologically evident in 29.2% of patients, symptomatic in 9.4%, and permanent in 2.7%. Independent predictors of any radiation-induced changes in multivariate analysis were a history of prior radiotherapy (OR 2.2, 95% CI 1.5–3.2, $p < 0.001$), increasing nidus maximum diameter (OR 1.1, 95% CI 1.0–1.3, $p < 0.020$), history of hemorrhage (OR 1.6, 95% CI 1.3–2.1, $p < 0.001$), increasing maximum follow-up (OR 1.0, 95% CI 1.0–1.1, $p < 0.001$), and increasing margin dose (OR 1.1, 95% CI 1.0–1.1, $p = 0.014$). Youden indices demonstrated that patients treated with a margin dose greater than 24 Gy were at greatest risk of developing radiation-induced changes (OR 1.8, 95% CI 1.3–2.3, $p < 0.001$). Similarly, patients treated with greater than 24 Gy were also significantly more likely to experience symptomatic (OR 1.9, 95% CI 1.3–2.8, $p = 0.001$) and permanent radiation-in-

TABLE 2. Patient and AVM characteristics*

Characteristic	Value
Male sex	1127 (50.4)
Age in yrs	
Mean $\pm$ SD	36.0 $\pm$ 16.5
Median	35
Range	2.8–99
Presentation	
Headache	342 (12.6)
Seizure	516 (19.1)
Neurological alteration	782 (29.0)
Hemorrhage	1060 (39.3)
Location	
Frontal, temporal	770 (34.9)
Parietal, occipital, corpus callosum	772 (32.7)
Cerebellum	518 (23.5)
Insula	32 (1.5)
Thalamus, basal ganglia, brainstem	264 (26.1)
Intraventricular	7 (0.3)
Associated aneurysm	259 (11.6)
Max diameter in cm	
Mean $\pm$ SD	2.3 $\pm$ 1.2
Median	2.2
Range	0.6–5.3
Vol in cm ³	
Mean $\pm$ SD	4.3 $\pm$ 4.9
Median	3
Range	0.1–24
Deep venous drainage	1231 (55.7)
Eloquence	1537 (69.6)
Diameter	
0–3 cm	1688 (75.4)
3–6 cm	527 (23.8)
>6 cm	16 (0.7)
Spetzler-Martin grade	
Mean $\pm$ SD	2.5 $\pm$ 0.8
Median	3
Range	1–5
Distribution	
I	236 (10.7)
II	835 (37.8)
III	918 (41.6)
IV	205 (9.3)
V	15 (0.7)
VRAS score	
Mean $\pm$ SD	2.2 $\pm$ 1.2
Median	2
Range	0–4
Distribution	
0	163 (7.4)

CONTINUED IN NEXT COLUMN »

» CONTINUED FROM PREVIOUS COLUMN

TABLE 2. Patient and AVM characteristics*

Characteristic	Value
VRAS score (<i>continued</i>)	
Distribution (<i>continued</i>)	
1	556 (25.2)
2	533 (24.2)
3	585 (26.5)
4	370 (16.8)
RBAS	
Mean $\pm$ SD	1.4 $\pm$ 0.6
Median	1.3
Range	0.4–3.5
History	
Embolization	463 (21.5)
Radiation	191 (8.5)
AVM surgery	110 (4.9)
CSF diversion	25 (1.1)

* Values are number of patients (%) unless otherwise indicated.

duced changes (OR 2.4, 95% CI 1.1–5.4, $p = 0.028$). When we controlled for independent predictors in multivariate analysis, patients treated with a margin dose of greater than 24 Gy were 1.5 times more likely to develop radiation-induced changes (95% CI 1.1–2.1, $p = 0.004$).

Assessment of Outcome

Favorable outcome (AVM obliteration without posttraumatic hemorrhage or permanent GKRS-associated symptoms) was achieved in 60.3% of patients. The univariate logistic regression analysis for predictors of unfavorable outcome is detailed in Table 4. Independent predictors of unfavorable outcome in the multivariate logistic regression analysis were higher nidus volume (OR 1.1, 95% CI 1.0–1.2, $p < 0.001$), prior AVM hemorrhage (OR 1.4, 95% CI 1.2–1.7, $p < 0.001$), prior embolization (OR 2.0, 95% CI 1.6–2.5, $p < 0.001$), eloquent AVM location (OR 1.3, 95% CI 1.0–1.6, $p = 0.009$), higher number of isocenters (OR 1.1, 95% CI 1.0–1.1, $p = 0.011$), and lower margin dose (OR 0.87, 95% CI 0.84–0.90, $p < 0.001$; Table 4).

The Spetzler-Martin grade ($p < 0.001$, AUC 0.60) and RBAS ($p < 0.001$, AUC 0.62) predicted outcome, but the VRAS score provided the best assessment ($p < 0.001$, AUC 0.67) (Fig. 2).

Discussion

AVMs pose a significant lifetime risk of intracranial

TABLE 3. Summary of radiosurgery treatment parameters

Characteristic	Mean $\pm$ SD	Median (range)
Margin dose, Gy	20.5 $\pm$ 3.7	20 (10–36)
Max dose, Gy	38.6 $\pm$ 7.4	40 (20–60)
No. of isocenters	3.7 $\pm$ 3.6	3 (1–18)
Isodose line, %	53.8 $\pm$ 9.6	50 (45–90)

FIG. 1. Modified Kaplan-Meier plot showing AVM obliteration rates over time following radiosurgery.

hemorrhage to affected patients, owing to their relatively young age at presentation and 2%–4% annual hemorrhage risk.^{2,9} Ruptured AVMs require treatment to prevent subsequent hemorrhage, which occurs at a higher rate after the initial hemorrhage.^{18,37} In contrast, the management of unruptured AVMs is currently a subject of intense debate.

Two recent prospective analyses comparing intervention to medical management for patients with unruptured AVMs, A Randomized Trial of Unruptured Brain AVMs (ARUBA) and the Scottish Audit of Intracranial Vascular Malformations (SAIVM) Study, showed significantly worse outcome with intervention that primarily repre-

TABLE 4. Predictors of overall unfavorable outcome*

Characteristic	Univariate			Multivariate		
	OR	95% CI	p Value	OR	95% CI	p Value
Male sex	1.010	0.850–1.202	0.906	—	—	—
Age at GKRS	1.003	0.997–1.008	0.335	—	—	—
Yr of GKRS	1.008	0.995–1.021	0.227	—	—	—
Yr of diagnosis	0.992	0.984–1.007	0.072	—	—	—
Time diagnosis to GKRS	1.001	0.999–1.002	0.203	—	—	—
Prior radiotherapy	0.810	0.657–1.000	0.049	0.696	0.475–1.016	0.061
Prior surgery	0.791	0.617–1.016	0.066	1.019	0.696–1.494	0.921
Prior embolization	2.331	1.889–2.876	<0.001	1.992	1.598–2.485	<0.001
Prior AVM hemorrhage	1.608	1.348–1.917	<0.001	1.444	1.181–1.740	<0.001
Max diameter	1.755	1.592–1.935	<0.001	—	—	—
Vol	1.159	1.129–1.189	<0.001	1.144	1.113–1.175	<0.001
Associated aneurysm	1.402	1.072–1.833	0.014	1.300	0.962–1.757	0.088
Eloquent location	1.371	1.132–1.662	0.001	1.322	1.072–1.630	0.009
Deep venous drainage	1.087	0.913–1.294	0.350	—	—	—
Max follow-up	0.999	0.998–1.001	0.783	—	—	—
Max dose	0.939	0.927–0.950	<0.001	1.025	0.934–1.123	0.602
Margin dose	0.832	0.811–0.856	<0.001	0.867	0.838–0.898	<0.001
Isodose	0.981	0.972–0.991	<0.001	1.016	0.963–1.071	0.549
No. of isocenters	1.053	1.025–1.082	<0.001	1.048	1.010–1.087	0.011

* Boldface type indicates independent predictors of unfavorable outcome.

FIG. 2. Graphs showing prediction of outcome according to the Spetzler-Martin grade, RBAS, and VRAS. ROC = receiver operating characteristic. Figure is available in color online only.

sented endovascular embolization.^{3,26} Despite the major methodological and short-term analyses of the results of both aforementioned studies as well as ample previously published data related to the risks of bleeding and death from an untreated AVM, enthusiasm for aggressive management of these patients has been reported to have waned among physician gatekeepers.^{32,33,38} Therefore, defining long-term outcomes is crucial to justifying AVM intervention to patients and physicians alike.

AVM Intervention With Gamma Knife Radiosurgery

Although resection remains the frontline management designed to obtain early obliteration of AVMs, GKRS has been widely accepted as an effective alternative to surgery for patients with smaller volume AVMs or with AVMs deeply located or in eloquent areas.^{20,39} GKRS causes progressive AVM obliteration by inducing endothelial injury, myointimal proliferation, collagen deposition, vessel hyalinization, and eventual vascular thrombosis and occlusion.³⁴ This process typically takes place over a period of 2–3 years, although realization of nidus obliteration on neuroimaging occurs at widely varying intervals due to differences in the intervals of radiological follow-up. In this study, the overall obliteration rate was 65%, and

the mean time to documentation of obliteration was 46 months after initial GKRS.

In the same manner as obliteration, complications such as radiation-induced changes and latency period hemorrhage also occur in a delayed fashion after GKRS.^{29,39} Radiological evidence of radiation-induced changes generally precedes nidus obliteration, typically occurring at an interval of 6–18 months after GKRS.⁴³ In this study, the rates of symptomatic and permanent radiation-induced changes were 9% and 3%, respectively, which were similar to those reported in prior single-center series.^{15,43} Patients treated with greater than 24 Gy were at the highest risk of radiation-induced changes. In general, GKRS has not been shown to significantly affect the natural hemorrhage risk of an AVM.²⁵ However, in our analysis, the annual hemorrhage rate during the latency period was low at 1.1%. Thus, GKRS may confer partial protection from AVM rupture during the time interval before obliteration is confirmed, but this finding may also be a reflection of selection and/or follow-up bias, because latency hemorrhage rates have been variably reported in the literature.

In the context of ARUBA and the SAIVM prospective AVM study, our findings suggest that radiosurgery confers a durable benefit over conservative management for

appropriately selected patients with unruptured AVMs. However, one should note that 39% of patients in this study presented with AVM hemorrhage. Additionally, a number of the patients with unruptured AVMs underwent prior intervention with embolization (22%), fractionated external beam radiotherapy (9%), and/or resection (5%), and would thus be ineligible for ARUBA. The differences in patient baseline characteristics and study design among our analysis, the initial findings from ARUBA, and the SAIVM AVM study are too great to clearly define a role for radiosurgery in management of unruptured AVMs. Nevertheless, we provide preliminary evidence from the collective experience of multiple tertiary referral centers for AVM treatment that radiosurgery can be acceptably offered as an alternative to medical therapy for a patient harboring an unruptured AVM.

Predictors of AVM Radiosurgery Outcomes

AVM volume has been consistently shown to have an inverse relationship with obliteration after GKRS across numerous studies.^{29,39} This finding was supported by our analysis, which found lower nidus volume to be an independent predictor of obliteration ($p < 0.001$). As one would expect, higher radiosurgical dose delivered to the nidus improves the odds of obliteration. Prior analyses have shown a sigmoid dose-response curve for AVM obliteration.¹⁶ Higher margin dose was independently associated with obliteration in our multivariate model ($p < 0.001$). Noneloquent location was also an independent predictor of obliteration ($p = 0.042$). It is also possible that the lower obliteration rates of eloquent AVMs are indicative of the hesitancy of treating physicians to deliver higher margin doses to eloquent nidi. AVMs in eloquent locations were treated with significantly lower mean peripheral doses (20.3 ± 3.7 Gy) than those in noneloquent locations (20.9 ± 3.7 Gy, $p = 0.001$).

In a number of prior AVM GKRS series, lower obliteration rates have been reported for embolized than for nonembolized nidi.^{6,29,39} In our study, lack of prior embolization was an independent predictor of obliteration ($p < 0.001$). However, the effect of embolization on an AVM's biology and its response to GKRS is incompletely understood.²⁷ The concern that liquid embolic agents may shield the nidus from the radiosurgical dose, by beam scattering or absorption, has been challenged by recent analyses.⁵⁻⁷ Embolization has been shown to promote angiogenesis in AVMs, which may increase radioresistance and decrease obliteration rates.^{8,40} Additionally, due to general inability to precisely control the distribution of an embolic agent, AVM embolization can result in an irregular, diffuse nidus, which is difficult to radiosurgically target and thus prone to incomplete obliteration after treatment.⁴¹ Over time, there was a significant increase in rates of obliteration ($p < 0.001$), suggesting that developments in GKRS technology and a refined understanding of the relationship between patient, AVM, and treatment factors and GKRS outcomes have, over time, yielded improved results.

Validation of Grading Systems for AVM Radiosurgery

Grading scales integrate individual predictors of outcome into an overall grade or score, which correlates with

posttreatment outcomes and, ultimately, serves to guide management decisions.^{24,29,35} The first, and most widely used, AVM grading system was described by Spetzler and Martin.³⁵ Although the Spetzler-Martin grade has been shown to correlate with AVM GKRS outcomes (AUC 0.60), it was originally proposed as a grading system for predicting operative morbidity and mortality after surgical intervention.^{21,35} Thus, it may not entirely reflect the factors that most significantly affect outcomes after AVM GKRS.

Subsequently, the RBAS was developed specifically for AVMs treated with radiosurgery and has been shown in our analysis to correlate with outcomes after GKRS (AUC 0.62), although its accuracy is comparable to that of the Spetzler-Martin grading system.^{29,30,42} However, the use of a mathematical formula to calculate the RBAS, and its output as a continuous variable, may detract from the ease and practicality of its application. We recognized that the durable success of the Spetzler-Martin grading scale is rooted not only in the ability to predict outcomes but also in its simplicity.³⁶ Therefore, the VRAS was designed to be a practical grading system analogous to the Spetzler-Martin grading scale, except with a focus on factors that enable the optimal prediction of outcomes for AVM radiosurgery rather than microsurgery.³⁹ Interestingly, the VRAS components were made up of a combination of Spetzler-Martin (eloquence) and RBAS (volume) components. Additionally, the best multivariate predictors of outcome in this study also comprise the VRAS (eloquence, volume, and history of hemorrhage). In this multicenter validation of the VRAS in 2236 patients, which represents, by far, the largest AVM GKRS series ever compiled, we showed that the VRAS was not only significantly associated with favorable outcome after AVM GKRS ($p < 0.001$), but also that it was superior to both the Spetzler-Martin grading scale and RBAS as a tool for assessing the suitability of an AVM nidus for treatment with GKRS (AUC 0.67).

The superior predictive capability of the VRAS score compared with the Spetzler-Martin grade and RBAS suggests that the composite radiological and clinical end point, favorable outcome, is affected more by AVM nidus volume, eloquent location, and prior AVM hemorrhage than AVM maximum diameter, deep venous drainage, deep AVM location, and patient age. While maximum diameter may be a sufficient indicator of nidus size for the purposes of predicting surgical outcomes, volume is more crucial for determining the optimal margin dose for radiosurgical targeting.¹⁵ Deep-seated AVMs and those with exclusively deep venous drainage are likely to be located in critical brain regions. However, these factors do not account for eloquent cortical AVMs with superficial venous drainage, which are more likely to be associated with symptomatic radiation-induced changes after radiosurgery.⁴³ Ruptured AVMs are more susceptible to hemorrhage during the latency period and thus unfavorable outcome, which is consistent with the effect of prior hemorrhage on an AVM's natural history.¹¹⁻¹³ Advanced patient age has been shown to correlate with increased AVM hemorrhage risk and adversely affect surgical outcomes.^{22,23} However, increasing patient age does not appear to consistently confer a higher complication rate after radiosurgery, suggesting that the risk-to-benefit profile for radiosurgery remains favorable

in the elderly AVM population.¹⁰ Although the VRAS is the simplest available grading system for predicting AVM radiosurgery outcomes, formulation of an individual assessment requires analysis of all patient, AVM, and treatment characteristics to determine outcomes following intervention.

Study Limitations

Although this study represents the largest series of AVM GKRS compiled to date, the analysis remains limited by the retrospective nature of the data collected from each of the participating institutions. Some of the data, particularly from the University of Pittsburgh Medical Center and the University of Virginia, were used to help construct prior radiosurgical AVM grading schemes. Thus, the overlapping cohorts represent a potential source for bias, but the lengths of follow-up in the current cohorts are longer than those used to derive the original grading systems.

In this study, 86% of cases of obliteration were confirmed by angiography. However, MRI was shown to be an adequate substitute for angiography in determining obliteration in the remaining patients.^{28,31} Thus, we believe that, despite the limitations, this study's multicenter design allows our findings to be generalizable to most AVM patients being considered for radiosurgical treatment.

Conclusions

GKRS for cerebral AVMs affords obliteration and avoids permanent complications in the majority of patients treated. Patient, AVM, and treatment parameters can be used to predict long-term outcomes following radiosurgery. Although all 3 currently used grading systems appear predictive of outcome, the VRAS provides a simple and reliable means to predict long-term outcome after GKRS.

References

- Al-Shahi R, Bhattacharya JJ, Currie DG, Papanastassiou V, Ritchie V, Roberts RC, et al: Scottish Intracranial Vascular Malformation Study (SIVMS): evaluation of methods, ICD-10 coding, and potential sources of bias in a prospective, population-based cohort. *Stroke* **34**:1156–1162, 2003
- Al-Shahi R, Warlow C: A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. *Brain* **124**:1900–1926, 2001
- Al-Shahi Salman R, White PM, Counsell CE, du Plessis J, van Beijnum J, Josephson CB, et al: Outcome after conservative management or intervention for unruptured brain arteriovenous malformations. *JAMA* **311**:1661–1669, 2014
- Altman DG: **Practical Statistics for Medical Research**. Boca Raton, FL: Chapman & Hall/CRC, 1999
- Andrade-Souza YM, Ramani M, Beachey DJ, Scora D, Tsao MN, terBrugge K, et al: Liquid embolisation material reduces the delivered radiation dose: a physical experiment. *Acta Neurochir (Wien)* **150**:161–164, 2008
- Andrade-Souza YM, Ramani M, Scora D, Tsao MN, terBrugge K, Schwartz ML: Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. *Neurosurgery* **60**:443–452, 2007
- Bing F, Doucet R, Lacroix F, Bahary JP, Darsaut T, Roy D, et al: Liquid embolization material reduces the delivered radiation dose: clinical myth or reality? *AJNR Am J Neuroradiol* **33**:320–322, 2012
- Buell TJ, Ding D, Starke RM, Webster Crowley R, Liu KC: Embolization-induced angiogenesis in cerebral arteriovenous malformations. *J Clin Neurosci* **21**:1866–1871, 2014
- Crawford PM, West CR, Chadwick DW, Shaw MD: Arteriovenous malformations of the brain: natural history in unoperated patients. *J Neurol Neurosurg Psychiatry* **49**:1–10, 1986
- Ding D, Xu Z, Yen CP, Starke RM, Sheehan JP: Radiosurgery for cerebral arteriovenous malformations in elderly patients: effect of advanced age on outcomes after intervention. *World Neurosurg* **84**:795–804, 2015
- Ding D, Yen CP, Starke RM, Xu Z, Sheehan JP: Effect of prior hemorrhage on intracranial arteriovenous malformation radiosurgery outcomes. *Cerebrovasc Dis* **39**:53–62, 2015
- Ding D, Yen CP, Starke RM, Xu Z, Sheehan JP: Radiosurgery for ruptured intracranial arteriovenous malformations. *J Neurosurg* **121**:470–481, 2014
- Ding D, Yen CP, Xu Z, Starke RM, Sheehan JP: Radiosurgery for patients with unruptured intracranial arteriovenous malformations. *J Neurosurg* **118**:958–966, 2013
- Fine JP: A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* **94**:496–509, 1999
- Flickinger JC, Kondziolka D, Pollock BE, Maitz AH, Lunsford LD: Complications from arteriovenous malformation radiosurgery: multivariate analysis and risk modeling. *Int J Radiat Oncol Biol Phys* **38**:485–490, 1997
- Flickinger JC, Pollock BE, Kondziolka D, Lunsford LD: A dose-response analysis of arteriovenous malformation obliteration after radiosurgery. *Int J Radiat Oncol Biol Phys* **36**:873–879, 1996
- Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat* **16**:1141–1154, 1988
- Gross BA, Du R: Natural history of cerebral arteriovenous malformations: a meta-analysis. *J Neurosurg* **118**:437–443, 2013
- Hartmann A, Mast H, Mohr JP, Koennecke HC, Osipov A, Pile-Spellman J, et al: Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation. *Stroke* **29**:931–934, 1998
- Kano H, Kondziolka D, Flickinger JC, Yang HC, Flannery TJ, Niranjan A, et al: Stereotactic radiosurgery for arteriovenous malformations, Part 4: management of basal ganglia and thalamus arteriovenous malformations. *J Neurosurg* **116**:33–43, 2012
- Kano H, Lunsford LD, Flickinger JC, Yang HC, Flannery TJ, Awan NR, et al: Stereotactic radiosurgery for arteriovenous malformations, Part 1: management of Spetzler-Martin Grade I and II arteriovenous malformations. *J Neurosurg* **116**:11–20, 2012
- Kim H, Abla AA, Nelson J, McCulloch CE, Bervini D, Morgan MK, et al: Validation of the supplemented Spetzler-Martin grading system for brain arteriovenous malformations in a multicenter cohort of 1009 surgical patients. *Neurosurgery* **76**:25–23, 2015
- Kim H, Al-Shahi Salman R, McCulloch CE, Stapf C, Young WL: Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors. *Neurology* **83**:590–597, 2014
- Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL: A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. *Neurosurgery* **66**:702–713, 2010
- Maruyama K, Kawahara N, Shin M, Tago M, Kishimoto J, Kurita H, et al: The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. *N Engl J Med* **352**:146–153, 2005
- Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, et al: Medical management with or without interventional therapy for unruptured brain arteriovenous malformations

- (ARUBA): a multicentre, non-blinded, randomised trial. **Lancet** **383**:614–621, 2014
27. Mouchtouris N, Jabbour PM, Starke RM, Hasan DM, Zanaty M, Theofanis T, et al: Biology of cerebral arteriovenous malformations with a focus on inflammation. **J Cereb Blood Flow Metab** **35**:167–175, 2015
 28. O'Connor TE, Friedman WA: Magnetic resonance imaging assessment of cerebral arteriovenous malformation obliteration after stereotactic radiosurgery. **Neurosurgery** **73**:761–766, 2013
 29. Pollock BE, Flickinger JC: Modification of the radiosurgery-based arteriovenous malformation grading system. **Neurosurgery** **63**:239–243, 2008
 30. Pollock BE, Flickinger JC: A proposed radiosurgery-based grading system for arteriovenous malformations. **J Neurosurg** **96**:79–85, 2002
 31. Pollock BE, Kondziolka D, Flickinger JC, Patel AK, Bissonette DJ, Lunsford LD: Magnetic resonance imaging: an accurate method to evaluate arteriovenous malformations after stereotactic radiosurgery. **J Neurosurg** **85**:1044–1049, 1996
 32. Pollock BE, Link MJ, Brown RD: The risk of stroke or clinical impairment after stereotactic radiosurgery for ARUBA-eligible patients. **Stroke** **44**:437–441, 2013
 33. Rutledge WC, Abla AA, Nelson J, Halbach VV, Kim H, Lawton MT: Treatment and outcomes of ARUBA-eligible patients with unruptured brain arteriovenous malformations at a single institution. **Neurosurg Focus** **37**(3):E8, 2014
 34. Schneider BF, Eberhard DA, Steiner LE: Histopathology of arteriovenous malformations after gamma knife radiosurgery. **J Neurosurg** **87**:352–357, 1997
 35. Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. **J Neurosurg** **65**:476–483, 1986
 36. Stapf C, Mast H, Sciacca RR, Berenstein A, Nelson PK, Gobin YP, et al: The New York Islands AVM Study: design, study progress, and initial results. **Stroke** **34**:e29–e33, 2003
 37. Stapf C, Mast H, Sciacca RR, Choi JH, Khaw AV, Connolly ES, et al: Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. **Neurology** **66**:1350–1355, 2006
 38. Starke RM, Sheehan JP, Ding D, Liu KC, Kondziolka D, Crowley RW, et al: Conservative management or intervention for unruptured brain arteriovenous malformations. **World Neurosurg** **82**:e668–e669, 2014
 39. Starke RM, Yen CP, Ding D, Sheehan JP: A practical grading scale for predicting outcome after radiosurgery for arteriovenous malformations: analysis of 1012 treated patients. **J Neurosurg** **119**:981–987, 2013
 40. Sure U, Battenberg E, Dempfle A, Tirakotai W, Bien S, Bertalanffy H: Hypoxia-inducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral arteriovenous malformations. **Neurosurgery** **55**:663–670, 2004
 41. Valle RD, Zenteno M, Jaramillo J, Lee A, De Anda S: Definition of the key target volume in radiosurgical management of arteriovenous malformations: a new dynamic concept based on angiographic circulation time. **J Neurosurg** **109** Suppl:41–50, 2008
 42. Wegner RE, Oysul K, Pollock BE, Sirin S, Kondziolka D, Niranjana A, et al: A modified radiosurgery-based arteriovenous malformation grading scale and its correlation with outcomes. **Int J Radiat Oncol Biol Phys** **79**:1147–1150, 2011
 43. Yen CP, Matsumoto JA, Wintermark M, Schwyzler L, Evans AJ, Jensen ME, et al: Radiation-induced imaging changes following Gamma Knife surgery for cerebral arteriovenous malformations. **J Neurosurg** **118**:63–73, 2013

Disclosures

Drs. Pieper and Grills report having stock ownership in and serving on the Board of Directors of Greater Michigan Gamma Knife, and Dr. Grills reports receiving funding for non-study-related research from Elekta through her institution. Dr. Lunsford reports being a consultant and owning stock in Elekta.

Author Contributions

Conception and design: Sheehan, Starke, Pierce, Huang, Kondziolka, Rodriguez-Mercado, Grills, Barnett, Lunsford. Acquisition of data: Sheehan, Starke, Kano, Ding, Lee, Mathieu, Whitesell, Pierce, Huang, Kondziolka, Yen, Feliciano, Rodriguez-Mercado, Almodovar, Pieper, Grills, Silva, Abbassy, Missios, Barnett. Analysis and interpretation of data: all authors. Drafting the article: Sheehan, Starke, Ding, Lee, Mathieu, Whitesell, Yen, Feliciano, Rodriguez-Mercado, Pieper, Barnett. Critically revising the article: Sheehan, Starke, Kano, Ding, Lee, Mathieu, Whitesell, Pierce, Huang, Kondziolka, Yen, Feliciano, Rodriguez-Mercado, Almodovar, Pieper, Grills, Silva, Abbassy, Missios, Lunsford. Reviewed submitted version of manuscript: Sheehan, Starke, Kano, Ding, Lee, Mathieu, Whitesell, Pierce, Huang, Kondziolka, Yen, Feliciano, Rodriguez-Mercado, Almodovar, Pieper, Grills, Silva, Abbassy, Missios, Barnett. Statistical analysis: Starke. Administrative/technical/material support: Sheehan, Kano, Ding, Lee, Mathieu, Whitesell, Pierce, Huang, Kondziolka, Yen, Feliciano, Rodriguez-Mercado, Almodovar, Pieper, Grills, Silva, Abbassy, Missios, Barnett, Lunsford. Study supervision: Sheehan, Starke, Kano, Mathieu, Pierce, Huang, Kondziolka, Yen, Feliciano, Rodriguez-Mercado, Almodovar, Pieper, Grills, Silva, Abbassy, Missios, Barnett, Lunsford.

Correspondence

Jason P. Sheehan, Department of Neurological Surgery, University of Virginia, Box 800212, Charlottesville, VA 22908. email: jsheehan@virginia.edu.